Lupin and Huons Join Hands To Bring Novel Dry Eye Treatment to Mexico

Lupin, a global pharmaceutical company, announced a licensing and supply agreement with Huons, a top Korean pharmaceutical company to enhance their ophthalmology offerings. The focus of the agreement is on registering and marketing Cyclosporine Ophthalmic Nanoemulsion in Mexico.

Cyclosporine Ophthalmic Nanoemulsion is a preservative-free remedy for dry eye syndrome and the recovery of corneal ulcers. This product uses nanotechnology to provide quicker relief of symptoms by boosting tear production in patients with decreased tear production. The therapy has already received authorization in South Korea, Peru, and multiple Middle Eastern nations.

“We are thrilled to partner with Huons to introduce this novel technology to patients in Mexico,” said Fabrice Egros, president of corporate development and growth markets at Lupin. “This addition to our ophthalmology portfolio strengthens our commitment to providing better healthcare and eye care solutions, ultimately improving patients’ quality of life and vision.”

According to Yohun Aum, senior director at Huons, the agreement is a significant achievement for the company. He expressed anticipation of a robust collaboration in delivering top-notch products for the Mexican market.

Based in Mumbai, India, Lupin is a company that creates and sells various types of branded and generic drugs, such as biotechnology products and active pharmaceutical ingredients (APIs), in more than 100 countries globally. Lupin is a leader in cardiology, anti-diabetes, and respiratory treatments, and also has a strong presence in various other therapeutic fields. At present, they rank as the third largest pharmaceutical company in the US based on prescriptions, and they consistently make significant investments in research and development.